Eli Lilly and Company launches Foundayo after U.S. Food and Drug Administration approval, offering a once-daily oral weight-loss option supported by ATTAIN trial data showing up to 27.3-pound average reduction.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Eli Lilly and Company announced that Foundayo (orforglipron) is now available in the United States for adults with obesity or overweight with weight-related medical conditions, following approval from the U.S. Food and Drug Administration on April 1, 2026. The once-daily oral therapy is indicated for chronic weight management when used alongside a reduced-calorie diet and increased physical activity. The company stated that the pill can be taken without food or water restrictions.
Patients can access Foundayo through LillyDirect and telehealth providers, with rollout to U.S. retail pharmacies beginning immediately. Lilly noted that the program is designed to simplify access from prescription to home delivery.
Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, said the therapy demonstrated meaningful weight reduction and that the company aimed to streamline access. He added that patients can connect with healthcare professionals, receive prescriptions, and obtain the medicine through home delivery, telehealth services, or local pharmacies.
Pricing and Access
Foundayo is available starting at $149 per month at the lowest dose for self-pay patients. Eligible commercially insured patients may pay as little as $25 per month using a savings card. Lilly also stated that eligible Medicare Part D beneficiaries may be able to obtain the medicine for $50 per month beginning July 1, 2026.
The company highlighted that insurance coverage for obesity medications remains inconsistent across U.S. health plans, with approximately half of individuals with employer-sponsored insurance lacking coverage. Lilly said expanded self-pay options are intended to improve access.
Clinical Trial Results
The approval and launch are supported by the ATTAIN clinical trial program. In ATTAIN-1 (NCT05869903), participants receiving the highest dose of Foundayo who remained on treatment lost an average of 27.3 pounds (12.4%) compared with 2.2 pounds (0.9%) in the placebo group. Across all participants regardless of completion, weight loss averaged 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo.
ATTAIN-2 (NCT05872620), a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial, evaluated multiple doses of orforglipron in adults with obesity or overweight and type 2 diabetes, further supporting the efficacy and safety profile of the therapy across a broader cardiometabolic population.
The ATTAIN program also showed reductions in cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across dose levels.
In addition, orforglipron has shown continued momentum across its broader clinical program, maintaining weight loss in patients transitioning from Wegovy and Zepbound in the ATTAIN-MAINTAIN study, while also outperforming oral semaglutide in the ACHIEVE-3 trial further reinforcing its competitive positioning against Novo Nordisk in the emerging oral GLP-1 market.
Safety Information
Use of Foundayo with other GLP-1 receptor agonists is not recommended. The safety and effectiveness in pediatric populations have not been established. The therapy carries a warning regarding potential thyroid tumors, including thyroid cancer. Patients are advised to monitor symptoms such as neck swelling, hoarseness, difficulty swallowing, or shortness of breath.
Common adverse reactions include nausea, constipation, diarrhea, vomiting, abdominal pain, indigestion, headache, fatigue, bloating, belching, heartburn, gas, and hair loss.
Healthcare providers and patients should review the full Prescribing Information and Medication Guide for complete details on indications, warnings, precautions, and safety considerations.
References
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S., 09 April 2026, Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. | Eli Lilly and Company
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.